Iowa Code § 124.208 - Schedule III — substances included

1. Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Benzphetamine. b. Chlorphentermine. c. Clortermine. d. Phendimetrazine. 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system: a. Any compound, mixture or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedules. b. Any suppository dosage form containing amobarbital, secobarbital, pentobarbital or any salt of any of these drugs and approved by the federal food and drug administration for marketing only as a suppository. c. Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof including but not limited to Fioricet. d. Chlorhexadol. e. Lysergic acid. f. Lysergic acid amide. g. Methyprylon. h. Sulfondiethylmethane. i. Sulfonethylmethane. j. Sulfonmethane. k. Tiletamine and zolazepam or any salt thereof, including the following: (1) Some trade or other names for a tiletamine-zolazepam combination product: Telazol. (2) Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)- cyclohexanone. (3) Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8- trimethylpyraxolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon. l. Ketamine, its salts, isomers, and salts of isomers. Some other names for ketamine: (+-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone. m. Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act. n. Embutramide. o. Perampanel, its salts, isomers, and salts of isomers. 4. Nalorphine. 5. Narcotic drugs. Unless specifically excepted or unless listed in another schedule: a. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: (1) Not more than one point eight grams of codeine per one hundred milliliters or not more than ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium. (2) Not more than one point eight grams of codeine per one hundred milliliters or not more than ninety milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. (3) Not more than one point eight grams of dihydrocodeine per one hundred milliliters or not more than ninety milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. (4) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. (5) Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. (6) Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. b. Any material, compound, mixture, or preparation containing the narcotic drug buprenorphine, or its salts. 6. Anabolic steroids. Unless specifically excepted in subsection 7 or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including their salts, esters, and ethers: a. 3[beta],17[beta]-dihydroxy-5[alpha]-androstane. b. 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane. c. 5[alpha]-androstan-3,17-dione. d. 1-androstenediol(3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene). e. 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene). f. 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene). g. 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene). h. 1-androstenedione (5[alpha]-androst-1-en-3,17-dione). i. 4-androstenedione (androst-4-en-3,17-dione). j. 5-androstenedione (androst-5-en-3,17-dione). k. Bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one). l. Boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one). m. Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one). n. Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one). o. Dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methyl- androst-1,4-dien-3-one). p. [Delta]1-dihydrotestosterone (also known as 1-testosterone)(17[beta]- hydroxy-5[alpha]-androst-1-en-3-one). q. 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one). r. Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one). s. Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene). t. Fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost- 4-en-3-one). u. Formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost- 1,4-dien-3-one). v. Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]furazan). w. 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one. x. 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one). y. 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-estr-4-en-3-one). z. Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one). aa. Mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one). ab. Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one). ac. Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene). ad. Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one). ae. 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane. af. 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane. ag. 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene. ah. 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy- 17[beta]-hydroxyestr-4-en-3-one). ai. Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one). aj. Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one). ak. Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one). al. Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one). am. 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17[beta]-hydroxy-17[alpha]- methyl-5[alpha]-androst-1-en-3-one) (also known as 17-[alpha]-methyl-1- testosterone). an. Nandrolone (17[beta]-hydroxyestr-4-en-3-one). ao. 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene). ap. 19-nor-4-androstenediol (3[alpha],17[beta]-dihydroxyestr-4-ene). aq. 19-nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene). ar. 19-nor-5-androstenediol (3[alpha],17[beta]-dihydroxyestr-5-ene). as. 19-nor-4-androstenedione (estr-4-en-3,17-dione). at. 19-nor-5-androstenedione (estr-5-en-3,17-dione). au. Norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one). av. Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one). aw. Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one). ax. Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one). ay. Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one). az. Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one). ba. Oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]- androstan-3-one). bb. Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]- pyrazole). bc. Stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one). bd. Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone). be. Testosterone (17[beta]-hydroxyandrost-4-en-3-one). bf. Tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon- 4,9,11-trien-3-one). bg. Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one). bh. Boldione (androsta-1,4-diene-3,17-dione). bi. Desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol); also known as madol. bj. 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione). bk. Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one or 2[alpha],17[alpha]-dimethyl-17[beta]-hydroxy-5[alpha]-androstan-3-one). bl. Prostanozol (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pyrazole or [3,2-c] pyrazole-5[alpha]-androstan-17[beta]-ol). bm. 5[alpha]-androstan-3,6,17-trione. bn. 6-bromo-androsta-1,4-diene-3,17-dione. bo. 6-bromo-androstan-3,17-dione. bp. 4-chloro-17[alpha]-methyl-androsta-1,4-diene-3,17[beta]-diol. bq. 4-chloro-17[alpha]-methyl-androst-4-ene-3[beta],17[beta]-diol. br. 4-chloro-17[alpha]-methyl-17[beta]-hydroxy-androst-4-en-3-one. bs. 4-chloro-17[alpha]-methyl-17[beta]-hydroxy-androst-4-ene-3,11-dione. bt. 2[alpha],17[alpha]-dimethyl-17[beta]-hydroxy-5[beta]-androstan-3-one. bu. 2[alpha],3[alpha]-epithio-17[alpha]-methyl-5[alpha]-androstan-17[beta]-ol. bv. estra-4,9,11-triene-3,17-dione. bw. [3,2-c]furazan-5[alpha]-androstan-17[beta]-ol. bx. 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one. by. 4-hydroxy-androst-4-ene-3,17-dione. bz. 17[beta]-hydroxy-androstano[2,3-d]isoxazole. ca. 17[beta]-hydroxy-androstano[3,2-c]isoxazole. cb. 3[beta]-hydroxy-estra-4,9,11-trien-17-one. cc. 17[alpha]-methyl-androsta-1,4-diene-3,17[beta]-diol. cd. 17[alpha]-methyl-5[alpha]-androstan-17[beta]-ol. ce. 17[alpha]-methyl-androstan-3-hydroxyimine-17[beta]-ol. cf. 6[alpha]-methyl-androst-4-ene-3,17-dione. cg. 17[alpha]-methyl-androst-2-ene-3,17[beta]-diol. ch. [3,2-c]pyrazole-androst-4-en-17[beta]-ol. 7. Exclusions — anabolic steroids. This section shall not apply to an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved for such administration. A person who prescribes, dispenses, or distributes such steroid for human use shall be considered to have prescribed, dispensed, or distributed an anabolic steroid subject to this section. This section shall not apply to estrogens, progestins, corticosteroids, or dehydroepiandrosterone. 8. The board by rule may except any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsections 2 and 3 of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in such combinations, quantity, proportion, or concentration as to vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system. 9. Hallucinogenic substances. a. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved for marketing by the United States food and drug administration. Other names: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1- ol; (-)-delta-9-(trans)-tetrahydrocannabinol. b. Any drug product in tablet or capsule form containing natural dronabinol (derived from the cannabis plant) or synthetic dronabinol (produced from synthetic materials) for which an abbreviated new drug application (ANDA) has been approved by the United States food and drug administration under section 505(j) of the Federal Food, Drug, and Cosmetic Act and which references as its listed drug the drug product identified in paragraph “a”. [C73, 75, 77, 79, 81, §204.208; 82 Acts, ch 1044, §5] 84 Acts, ch 1013, §10; 88 Acts, ch 1024, §2; 91 Acts, ch 8, §4; 91 Acts, ch 37, §1 C93, §124.208 94 Acts, ch 1009, §11 – 13; 95 Acts, ch 6, §1; 2000 Acts, ch 1140, §8 – 10; 2001 Acts, ch 58, §2; 2003 Acts, ch 53, §6, 7; 2007 Acts, ch 8, §10 – 12; 2008 Acts, ch 1010, §3, 4; 2012 Acts, ch 1122, §3; 2014 Acts, ch 1056, §3, 4; 2017 Acts, ch 27, §6, 11; 2020 Acts, ch 1023, §9, 13; 2021 Acts, ch 93, §27 – 30, 38; 2025 Acts, ch 10, §5, 6, 10; 2025 Acts, ch 30, §105 Referred to in §124.201, 124.202, 124.303, 126.2 Code editor directive applied Subsection 6, paragraphs a, h, v, z, aa, am, ay, ba, bb, bc, bk, and bl stricken and rewritten Subsection 6, NEW paragraphs bm, bn, bo, bp, bq, br, bs, bt, bu, bv, bw, bx, by, bz, ca, cb, cc, cd, ce, cf, cg, and ch